0 0 0 0 0 0.0148148148148148 0 0.0222222222222222
Sign Up Today X
Thanks for submitting the form.
Stockreport

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]

InflaRx N.V. (IFRX)  More Company Research Source: Yahoo! Finance
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL. Camilla Chong, MD, Chief Medical Officer of InflaRx , commented: “We are proud to announce that all of our submitted abstracts have been accepted for presentation at the AAD Annual Meeting, reflecting the considerable scientific work that has gone into the clinical development of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS). In HS, we are presenting for the first time the reduction in draining tunnels (dTs) with vilobelimab, and the relevance of our modified HiSCR which weighs the importance of these dTs which have a devastating impact on patients with HS.” Oral poster presentation: Vilobelimab Safety in Pyoderma Gangrenosum [Read more]
IMPACT SNAPSHOT EVENT TIME: IFRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
IFRX alerts
from News Quantified
IFRX
NEWS
IFRX
Earnings
IFRX
Analyst Actions
IFRX
SEC Filings
Stockreport

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]

InflaRx N.V.  (IFRX) 
More Company Research Source: Yahoo! Finance
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL. Camilla Chong, MD, Chief Medical Officer of InflaRx , commented: “We are proud to announce that all of our submitted abstracts have been accepted for presentation at the AAD Annual Meeting, reflecting the considerable scientific work that has gone into the clinical development of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS). In HS, we are presenting for the first time the reduction in draining tunnels (dTs) with vilobelimab, and the relevance of our modified HiSCR which weighs the importance of these dTs which have a devastating impact on patients with HS.” Oral poster presentation: Vilobelimab Safety in Pyoderma Gangrenosum [Read more]
IMPACT SNAPSHOT
EVENT TIME:
IFRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS